Both faculty members and the majority of MO surveyed use rituximab monotherapy, although another common choice was BR. Dr Kahl notes that when BR is used in elderly patients consideration should be given to reducing the dose of bendamustine to, for example, 70 milligrams per square meter.

Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014;15(4):424-35. Abstract

Kenkre VP, Kahl BS. What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J 2012;18(5):383-9. Abstract

Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381(9873):1203-10. Abstract